RE:RE:RE:RE:RE:nice jumpBasically we may see 6 x $2.5M payments starting Apr 1st so these will show up in Q2 report due say mid-Aug. Perhaps this can be shifted with an enticement such as warrants or a debt-share conversion. Merck payments are more speculative. In the worst case we would need to provide these payments by mid-2020. In the best case we need to pay much less due to the staggered Ph 3 plans and applications. Management obviously know all of this and perhaps more, so they say that they have the runway through 2020. I guess we need to take that at face value but I would like to know more details (obviously). If Merck (or J&J) decide to acquire the SP will ratchet up since if the first NDA obtains market approval then the valuation is probably $400M given the pipeline propect. These big companies will probably wait until the results are more assured before passing the 10% holdings and marking their claim if they are interested at all that is. Ideally for investors we do not get bought out and the company goes into marketing and sales, unless it can carve off each product rather than selling the whole shebang. If the marketing of the first approved product generates $100M/a sales x 50% margin x 10x PE ratio then that would generate a $500M market cap within say 2 years for a rapid adoption rate. The other approved products will take the company higher. This is why I am here at this early stage and by no means will the path be simple although the risk is lower today than a couple of years ago and the valuation is lower so that means a bargain relatively speaking.